OBJECTIVE: To assess whether an average of 10 years of lifestyle intervention designed to reduce weight and increase physical activity lowers the prevalence of cognitive impairment among adults at increased risk due to type 2 diabetes and obesity or overweight. METHODS: Central adjudication of mild cognitive impairment and probable dementia was based on standardized cognitive test battery scores administered to 3,802 individuals who had been randomly assigned, with equal probability, to either the lifestyle intervention or the diabetes support and education control. When scores fell below a prespecified threshold, functional information was obtained through proxy interview. RESULTS: Compared with control, the intensive lifestyle intervention induced and maintained marked differences in weight loss and self-reported physical activity throughout follow-up. At an average (range) of 11.4 (9.5-13.5) years after enrollment, when participants' mean age was 69.6 (54.9-87.2) years, the prevalence of mild cognitive impairment and probable dementia was 6.4% and 1.8%, respectively, in the intervention group, compared with 6.6% and 1.8%, respectively, in the control group (p = 0.93). The lack of an intervention effect on the prevalence of cognitive impairment was consistent among individuals grouped by cardiovascular disease history, diabetes duration, sex, and APOE ε4 allele status (all p ≥ 0.50). However, there was evidence (p = 0.03) that the intervention effect ranged from benefit to harm across participants ordered from lowest to highest baseline BMI. CONCLUSIONS: Ten years of behavioral weight loss intervention did not result in an overall difference in the prevalence of cognitive impairment among overweight or obese adults with type 2 diabetes. CLINICALTRIALSGOV IDENTIFIER: NCT00017953 (Action for Health in Diabetes). LEVEL OF EVIDENCE: This study provides Class II evidence that for overweight adults with type 2 diabetes, a lifestyle intervention designed to reduce weight and increase physical activity does not lower the risk of cognitive impairment.
OBJECTIVE: To assess whether an average of 10 years of lifestyle intervention designed to reduce weight and increase physical activity lowers the prevalence of cognitive impairment among adults at increased risk due to type 2 diabetes and obesity or overweight. METHODS: Central adjudication of mild cognitive impairment and probable dementia was based on standardized cognitive test battery scores administered to 3,802 individuals who had been randomly assigned, with equal probability, to either the lifestyle intervention or the diabetes support and education control. When scores fell below a prespecified threshold, functional information was obtained through proxy interview. RESULTS: Compared with control, the intensive lifestyle intervention induced and maintained marked differences in weight loss and self-reported physical activity throughout follow-up. At an average (range) of 11.4 (9.5-13.5) years after enrollment, when participants' mean age was 69.6 (54.9-87.2) years, the prevalence of mild cognitive impairment and probable dementia was 6.4% and 1.8%, respectively, in the intervention group, compared with 6.6% and 1.8%, respectively, in the control group (p = 0.93). The lack of an intervention effect on the prevalence of cognitive impairment was consistent among individuals grouped by cardiovascular disease history, diabetes duration, sex, and APOE ε4 allele status (all p ≥ 0.50). However, there was evidence (p = 0.03) that the intervention effect ranged from benefit to harm across participants ordered from lowest to highest baseline BMI. CONCLUSIONS: Ten years of behavioral weight loss intervention did not result in an overall difference in the prevalence of cognitive impairment among overweight or obese adults with type 2 diabetes. CLINICALTRIALSGOV IDENTIFIER: NCT00017953 (Action for Health in Diabetes). LEVEL OF EVIDENCE: This study provides Class II evidence that for overweight adults with type 2 diabetes, a lifestyle intervention designed to reduce weight and increase physical activity does not lower the risk of cognitive impairment.
Authors: Brenda L Plassman; John W Williams; James R Burke; Tracey Holsinger; Sophiya Benjamin Journal: Ann Intern Med Date: 2010-06-14 Impact factor: 25.391
Authors: Michael L Alosco; Mary Beth Spitznagel; Gladys Strain; Michael Devlin; Ronald Cohen; Robert Paul; Ross D Crosby; James E Mitchell; John Gunstad Journal: Obesity (Silver Spring) Date: 2013-10-15 Impact factor: 5.002
Authors: Mark A Espeland; Stephen R Rapp; George A Bray; Denise K Houston; Karen C Johnson; Abbas E Kitabchi; Andrea L Hergenroeder; Jeff Williamson; John M Jakicic; Brent van Dorsten; Stephen B Kritchevsky Journal: J Gerontol A Biol Sci Med Sci Date: 2014-03-11 Impact factor: 6.053
Authors: Donna H Ryan; Mark A Espeland; Gary D Foster; Steven M Haffner; Van S Hubbard; Karen C Johnson; Steven E Kahn; William C Knowler; Susan Z Yanovski Journal: Control Clin Trials Date: 2003-10
Authors: Fumiko Irie; Annette L Fitzpatrick; Oscar L Lopez; Lewis H Kuller; Rita Peila; Anne B Newman; Lenore J Launer Journal: Arch Neurol Date: 2008-01
Authors: Roberto Elosua; Serkalem Demissie; L Adrienne Cupples; James B Meigs; Peter W F Wilson; Ernst J Schaefer; Dolores Corella; Jose M Ordovas Journal: Obes Res Date: 2003-12
Authors: Jessica L Unick; Daniel Beavers; John M Jakicic; Abbas E Kitabchi; William C Knowler; Thomas A Wadden; Rena R Wing Journal: Diabetes Care Date: 2011-08-11 Impact factor: 19.112
Authors: Saion Chatterjee; Sanne A E Peters; Mark Woodward; Silvia Mejia Arango; G David Batty; Nigel Beckett; Alexa Beiser; Amy R Borenstein; Paul K Crane; Mary Haan; Linda B Hassing; Kathleen M Hayden; Yutaka Kiyohara; Eric B Larson; Chung-Yi Li; Toshiharu Ninomiya; Tomoyuki Ohara; Ruth Peters; Tom C Russ; Sudha Seshadri; Bjørn H Strand; Rod Walker; Weili Xu; Rachel R Huxley Journal: Diabetes Care Date: 2015-12-17 Impact factor: 19.112
Authors: Mark A Espeland; Owen Carmichael; Kathleen Hayden; Rebecca H Neiberg; Anne B Newman; Jeffery N Keller; Thomas A Wadden; Stephen R Rapp; James O Hill; Edward S Horton; Karen C Johnson; Lynne Wagenknecht; Rena R Wing Journal: J Gerontol A Biol Sci Med Sci Date: 2018-03-14 Impact factor: 6.053
Authors: Kathryn Demos McDermott; Samantha E Williams; Mark A Espeland; Kirk Erickson; Rebecca Neiberg; Thomas A Wadden; R Nick Bryan; Lisa Desiderio; Regina L Leckie; Lucy H Falconbridge; John M Jakicic; Miguel Alonso-Alonso; Rena R Wing Journal: Obesity (Silver Spring) Date: 2019-05-21 Impact factor: 5.002
Authors: Sheri J Hartman; Sandahl H Nelson; Catherine R Marinac; Loki Natarajan; Barbara A Parker; Ruth E Patterson Journal: Psychooncology Date: 2019-06-27 Impact factor: 3.894
Authors: Jaimie C Hunter; Elizabeth P Handing; Ramon Casanova; Maragatha Kuchibhatla; Michael W Lutz; Santiago Saldana; Brenda L Plassman; Kathleen M Hayden Journal: Alzheimers Dement Date: 2018-02-01 Impact factor: 21.566
Authors: Francesco Vadini; Paola G Simeone; Andrea Boccatonda; Maria T Guagnano; Rossella Liani; Romina Tripaldi; Augusto Di Castelnuovo; Francesco Cipollone; Agostino Consoli; Francesca Santilli Journal: Int J Obes (Lond) Date: 2020-01-21 Impact factor: 5.095
Authors: Mark A Espeland; Owen Carmichael; Sevil Yasar; Christina Hugenschmidt; William Hazzard; Kathleen M Hayden; Stephen R Rapp; Rebecca Neiberg; Karen C Johnson; Siobhan Hoscheidt; Michelle M Mielke Journal: Alzheimers Dement Date: 2018-07-05 Impact factor: 21.566
Authors: Felicia R Simpson; Nicholas M Pajewski; Barbara Nicklas; Stephen Kritchevsky; Alain Bertoni; Frank Ingram; Daniel Ojeranti; Mark A Espeland Journal: J Gerontol A Biol Sci Med Sci Date: 2020-09-25 Impact factor: 6.053
Authors: Mark A Espeland; Gareth R Dutton; Rebecca H Neiberg; Owen Carmichael; Kathleen M Hayden; Karen C Johnson; Robert W Jeffery; Laura D Baker; Delilah R Cook; Dalane W Kitzman; Stephen R Rapp Journal: J Gerontol A Biol Sci Med Sci Date: 2018-10-08 Impact factor: 6.053